TrialRMD open2025
Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON.
Yannick Allanore et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papercites it